US Edition
Published • loading... • Updated
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar - Eli Lilly (NYSE:LLY)
The trial enrolled more than 2,700 adults and found a 16% lower risk of major cardiovascular events, while Lilly plans a diabetes filing by quarter-end.
- On Thursday, Eli Lilly and Company announced positive results from the ACHIEVE-4 trial, showing Foundayo reduced the risk of major adverse cardiovascular events by 16% compared to insulin glargine in adults with type 2 diabetes.
- The trial results directly address FDA concerns regarding potential liver injury, as the study found no hepatic safety signals consistent with earlier ACHIEVE and ATTAIN program findings.
- Foundayo demonstrated superior improvements in A1C levels and body weight at 52 weeks, while patients experienced a 57% lower risk of all-cause death versus the insulin glargine group.
- Eli Lilly and Company plans to submit Foundayo for type 2 diabetes approval by the end of the second quarter, utilizing the National Priority Review Voucher to accelerate market entry.
- Competition with Danish rival Novo Nordisk intensifies as its oral Wegovy has been available since January, with both firms racing to capture the growing oral GLP-1 diabetes market.
Insights by Ground AI
14 Articles
14 Articles
Coverage Details
Total News Sources14
Leaning Left0Leaning Right1Center7Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
12%
Factuality
To view factuality data please Upgrade to Premium
